3-Bromo-4-methylpyridine → N-(5-(Cyclopropylcarbamoyl)-2-methylphenyl)-5-(4-methylpyridin-3-yl)thiophene-2-carboxamide
反応式
[CH:1]1([NH:4][C:5]([C:7]2[CH:8]=[CH:9][C:10]([CH3:24])=[C:11]([NH:13][C:14]([C:16]3[S:20][C:19](B(O)O)=[CH:18][CH:17]=3)=[O:15])[CH:12]=2)=[O:6])[CH2:3][CH2:2]1.Br[C:26]1[CH:27]=[N:28][CH:29]=[CH:30][C:31]=1[CH3:32]>>[CH:1]1([NH:4][C:5]([C:7]2[CH:8]=[CH:9][C:10]([CH3:24])=[C:11]([NH:13][C:14]([C:16]3[S:20][C:19]([C:26]4[CH:27]=[N:28][CH:29]=[CH:30][C:31]=4[CH3:32])=[CH:18][CH:17]=3)=[O:15])[CH:12]=2)=[O:6])[CH2:3][CH2:2]1参加物
3
実験手順
The title compound was prepared by coupling 5-(5-(cyclopropylcarbamoyl)-2-methylphenylcarbamoyl)thiophen-2-ylboronic acid (Example 210, Step A) with commercially available 3-bromo-4-methylpyridine using the method described in Step B of Example 136 to afford a white solid after purification by reverse phase preparative HPLC (Example 212). HPLC Ret time=1.99 min. LCMS [M+H]+ 392.3.
後処理
- customto afford a white solid
- customafter purification by reverse phase preparative HPLC (Example 212)